Inventiva S.A. ADR (IVA) News

Inventiva S.A. ADR (IVA): $3.66

-0.14 (-3.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter IVA News Items

IVA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IVA News Highlights

  • IVA's 30 day story count now stands at 7.
  • Over the past 19 days, the trend for IVA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • ARCE, DRUG and ED are the most mentioned tickers in articles about IVA.

Latest IVA News From Around the Web

Below are the latest news stories about INVENTIVA SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.

Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst

Last week, Inventiva (NASDAQ: IVA) announced a licensing and collaboration agreement with Sino Biopharm's subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to develop and commercialize lanifibranor in Greater China. Regardless of CTTQ's decision on lanifibranor's clinical development pathway in China, HC Wainwright notes that Sino Biopharm is a vertically-integrated company with substantial R&D, manufacturing, sales, and marketing capability. The analyst regards the collaboration as a fin

Yahoo | September 26, 2022

Inventiva (IVA) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Inventiva (IVA - Research Report) today and set a price target of $36.00. The company's shares closed yesterday at $3.90.Arce covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Assembly Biosciences, and Aurinia Pharmaceuticals. According to TipRanks, Arce has an average return of 5.6% and a 37.89% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inventiva with a $36.00 average price target.

Jason Carr on TipRanks | September 23, 2022

Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

Inventiva (NASDAQ: IVA) and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan. Inventiva will receive an upfront payment of $12 million, and $5 million are also expected in the short term if certain clinical milestones are met. Inventiva has the

Yahoo | September 22, 2022

Inventiva reports its 2022 first-half financial results and provides a corporate update

Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva’s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flowInventiva entered into a credit facility for up to €50 million, subject to conditions, and a related warrant agreement with the European Investment Bank (EIB)2Inventiva raised approximately €14.7 million through a combin

Yahoo | September 22, 2022

Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater ChinaLanifibranor is an orally-available small molecule with breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) following a positive Phase IIb trial in patients with non-alcoholic steatohepatitis (NASH). Lanifibranor is currently evaluated in a pivotal Phase III trial in NASHInventiva will receive a $12 million upfront, $5

Yahoo | September 21, 2022

Here's Why Inventiva S.A. Sponsored ADR (IVA) is Poised for a Turnaround After Losing 18.4% in 4 Weeks

Inventiva S.A. Sponsored ADR (IVA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | September 8, 2022

Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results

Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 half-year financial results on Thursda

Yahoo | September 7, 2022

Inventiva Reports 2022 First-Half Financial Information¹

Cash position2 at €87.2 m as of June 30, 2022Revenues of €0.1 m in H1 2022Inventiva entered into a finance loan and a warrant agreement for up to €50 million with the European Investment Bank (EIB)Inventiva raised approximately €14.6m through a combination of its At-The-Market program (for €9.3m in gross proceeds) and new State backed bank financing (for €5.3m)Cash runway extended until the end of second quarter 2023 without taking into account the €50m finance loan from the EIB Daix (France), L

Yahoo | July 28, 2022

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available

Yahoo | July 21, 2022

Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D

The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and type-2 diabetes (T2D)The primary efficacy endpoint will be based on improvement in HbA1c Secondary efficacy endpoints include changes in liver enzymes, markers of glycemic control, lipid metabolism, inflammation and body fat compositionPublication of toplin

Yahoo | July 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7106 seconds.